Trial Profile
Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cixutumumab (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 01 Jul 2021 Results published in the Breast Cancer Research and Treatment
- 11 Mar 2020 Status changed from active, no longer recruiting to completed.
- 04 Jun 2014 Primary endpoint 'Progression-free-survival-duration' has not been met according to results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.